{
  "id": "mhgap#risk_safety_ab69ee83",
  "content": "EPI1. In adults with established status epilepticus, i.e. seizures\npersisting after the first-line agent (benzodiazepine-resistant\nstatus epilepticus), which antiseizure medicines are associated\nwith better clinical outcomes (stopping seizures and with less\nadverse effects)?\nRecommendation (update): In adults with established status epilepticus, i.e. seizures persisting after\ntwo doses of benzodiazepines, either intravenous fosphenytoin, intravenous\nphenytoin, intravenous levetiracetam, intravenous phenobarbital or\nintravenous valproic acid (sodium valproate) should be considered with\nappropriate monitoring. The choice of these medicines depends on local\nresources, including availability and facilities for monitoring.\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification y There is insufficient evidence to recommend\ny A new systematic review was conducted: Sharma et lacosamide and diazepam infusion at this time.\nal., 2023 (8 RCTs).12\nRemarks\ny There is low- to moderate-quality evidence that\ny Status epilepticus is a medical emergency which can\nthere is no clinically important difference in efficacy\nlead to profound systemic and neurological damage\nbetween intravenous fosphenytoin, levetiracetam,\nand is associated with significant short-term and\nphenytoin or sodium valproate for the treatment\nlong-term mortality. Timely control of status\nof benzodiazepine-resistant status epilepticus\nepilepticus is of paramount importance to improve\nin adults. There is low-quality evidence that\nthe outcomes.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "medium",
    "topics": [
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety EPI1. In adults with established status epilepticus, i.e. seizures\npersisting after the first-line agent (benzodiazepine-resistant\nstatus epilepticus), which antiseizure medicines are associated\nwith better clinical outcomes (stopping seizures and with less\nadverse effects)?\nRecommendation (update): In adults with established status epilepticus, i.e. seizures persisting after\ntwo doses of benzodiazepines, either intravenous fosphenytoin, intravenous\nphenytoin, intravenous levetiracetam, intravenous phenobarbital or\nintravenous valproic acid (sodium valproate) should be considered with\nappropriate monitoring. The choice of these medicines depends on local\nresources, including availability and facilities for monitoring.\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification y There is insufficient evidence to recommend\ny A new systematic review was conducted: Sharma et lacosamide and diazepam infusion at this time.\nal., 2023 (8 RCTs).12\nRemarks\ny There is low- to moderate-quality evidence that\ny Status epilepticus is a medical emergency which can\nthere is no clinically important difference in efficacy\nlead to profound systemic and neurological damage\nbetween intravenous fosphenytoin, levetiracetam,\nand is associated with significant short-term and\nphenytoin or sodium valproate for the treatment\nlong-term mortality. Timely control of status\nof benzodiazepine-resistant status epilepticus\nepilepticus is of paramount importance to improve\nin adults. There is low-quality evidence that\nthe outcomes. Epi1. in adults with established status epilepticus, i.e."
}